Avenue Therapeutics, Inc. has filed a prospectus related to the resale of 33,080,598 shares of common stock by selling stockholders. These shares are comprised of Series A and Series B Warrant Shares, which were issued in a private placement that closed on January 9, 2024. The selling stockholders may sell these shares at any time through various methods such as open market transactions or private sales. The proceeds from the sale of the shares will go directly to the selling stockholders, and Avenue Therapeutics will not receive any proceeds from these sales. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on The Nasdaq Capital Market under the symbol 'ATXI.' The last reported sale price of Avenue Therapeutics' common stock was $0.15 per share as of January 31, 2024. The prospectus also includes information on the risks involved in investing in the securities and states that the SEC has not approved or disapproved the securities, nor have they passed upon the accuracy or adequacy of the prospectus.

Avenue Therapeutics, Inc. has filed a prospectus related to the resale of 33,080,598 shares of common stock by selling stockholders. These shares are comprised of Series A and Series B Warrant Shares, which were issued in a private placement that closed on January 9, 2024. The selling stockholders may sell these shares at any time through various methods such as open market transactions or private sales. The proceeds from the sale of the shares will go directly to the selling stockholders, and Avenue Therapeutics will not receive any proceeds from these sales. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on The Nasdaq Capital Market under the symbol 'ATXI.' The last reported sale price of Avenue Therapeutics' common stock was $0.15 per share as of January 31, 2024. The prospectus also includes information on the risks involved in investing in the securities and states that the SEC has not approved or disapproved the securities, nor have they passed upon the accuracy or adequacy of the prospectus.